Ocugen

Ocugen

Ocugen

Ocugen is a biotechnology company focused on developing novel biologicals targeting unmet medical needs in treating complex eye diseases including dry agerelated macular degeneration (dry AMD), retinitis pigmentosa (RP) and wet agerelated macular degenera
Raised
$13.5M
Follow us
Alexa global traffic share
Latest funding
$7,500,000
Venture capital (Series B) - 2017
John Zhang Frank Leo Lancaster Group +1
$6,000,000
Venture capital (Series A) - 2016
EB5 Life Sciences
Team Size
1–10
Employees
Technical.ly

Funding news about Ocugen

Funding
$6,000,000 Venture capital (Series A)
prnewswire , biospace

Ocugen Closes $6 Million in Series A Funding